


Letter to the Editor | Published: 10 May 2016

Successful hematopoietic stem cell mobilization with vinorelbine and filgrastim in germ cell tumor

[Fabiana Aguiar Carneiro-Silva](#) , [Denise Menezes Brunetta](#), [Jacques Kaufman](#), [João Paulo Vasconcelos Leitão](#), [Karine Sampaio Nunes Barroso](#), [Suzanna Araújo Tavares Barbosa](#), [Luciana Maria de Barros Carlos](#) & [Fernando Barroso-Duarte](#)

Clinical and Experimental Medicine **17**, 417–418 (2017)

323 Accesses | [Metrics](#)

Abstract

Germ cell tumor (GCT) is the most frequent cancer in young men and is highly curable. Almost 80 % of patients with the disease in an advanced stage achieve a reliable response to cisplatin combination chemotherapy. For relapsing or refractory disease, autologous hematopoietic stem cell transplantation (HSCT) is an effective therapy. The two most used mobilization strategies for HSC collection are filgrastim alone or filgrastim after chemotherapy (chemomobilization). HSC collection with filgrastim mobilization can be difficult, especially in highly treated patients. While the addition of chemotherapy improves mobilization and reduces the number of apheresis sessions, it can increase morbidity rate as well. We describe a case of a 45-year-old male with classical seminoma who was

submitted to orchiectomy. Two months after, he presented progression of the tumor. He received four cycles of cisplatin, etoposide and bleomycin, with residual retroperitoneal mass and cervical lymphadenopathy. Further, he was submitted to three more cycles of cisplatin, ifosfamide and paclitaxel. Thereupon, he showed partial response. At that moment, autologous HSC transplantation was considered. In the first mobilization, filgrastim alone was used without success in harvesting. The second mobilization consisted of vinorelbine at day 1 (35 mg/m^2) and filgrastim ($16 \text{ }\mu\text{g/kg}$) started at day 5. The peak of CD34+ cells in peripheral blood was 32.6×10^6 cells/L on day 8, with 4.73×10^6 cells/kg CD34+ collected on days 8 and 9. The benefits of this scheme include: (a) outpatient administration, (b) fewer doses of filgrastim, (c) minimal risk of febrile neutropenia and (d) reliable prediction of collection day. For these reasons, we conclude that vinorelbine chemomobilization is a great option for GCT, particularly in patients with high risk of mobilization failure. Furthermore, it requires less resource usage, hospitalizations and transfusions than conventional chemomobilization.

This is a preview of subscription content, [access via your institution](#).

References

- 1.

Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. *N Engl J Med.* 2007;357:340–8.

2. 2.

Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. *Bone Marrow Transplant.* 2009;43:181–95.

3. 3.

Bargetzi MJ, Passweg J, Baertschi E, Schoenenberger A, Gwerder C, Tichelli A, et al. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. *Bone Marrow Transplant.* 2003;31:99–103.
<http://www.nature.com/bmt/journal/v31/n2/pdf/1703787a.pdf>.

4. 4.

Heizmann M, O’Meara AC, Moosmann PR, Heijnen IAFM, Zuberbühler M, Fernandez P, et al. Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma. *Bone Marrow Transplant.* 2009;44:75–9.

5. 5.

Samaras P, Pfrommer S, Seifert B, Petrausch U, Mischo A, Schmidt A, et al. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34(+) hematopoietic progenitor cell mobilization in patients with multiple myeloma. *Biol Blood Marrow Transplant.* 2015;21:74–80.

6. 6.

Fle A, Droz J. Importance of surgery as salvage treatment after high dose chemotherapy failure in germ cell tumors. *J Urol.* 2001;165:1920–6.

7. 7.

Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. *J Clin Oncol.* 1998;16:2500–4.

Author information

Affiliations

1. Hematology Division, Walter Cantidio University Hospital, Federal University of Ceara, Rua Capitão Francisco Pedro, 1290. Rodolfo Teofilo, Fortaleza, CE, 60.430-270, Brazil

Fabiana Aguiar Carneiro-Silva, Denise
Menezes Brunetta, Jacques Kaufman, João
Paulo Vasconcelos Leitão, Karine Sampaio
Nunes Barroso & Fernando Barroso-Duarte

2. Center of Hematology and Hemotherapy of
Ceara, HEMOCE, Fortaleza, CE, Brazil

Denise Menezes Brunetta, Suzanna Araújo
Tavares Barbosa & Luciana Maria de Barros
Carlos

Corresponding author

Correspondence to [Fabiana Aguiar Carneiro-Silva](#).

Ethics declarations

Conflict of interest

The authors have no conflict of interest.

Rights and permissions

[Reprints and Permissions](#)

About this article

Cite this article

Carneiro-Silva, F.A., Brunetta, D.M., Kaufman, J. *et al.* Successful hematopoietic stem cell mobilization with vinorelbine and filgrastim in germ cell tumor.

Clin Exp Med **17**, 417–418 (2017).

<https://doi.org/10.1007/s10238-016-0425-2>

- Received 03 March 2016
- Accepted 27 April 2016
- Published 10 May 2016
- Issue Date August 2017
- DOI <https://doi.org/10.1007/s10238-016-0425-2>

Keywords

- Hematopoietic Stem Cell Transplantation
- Febrile Neutropenia
- Vinorelbine
- Germ Cell Tumor
- Filgrastim

Not logged in - 189.90.161.13

Not affiliated

SPRINGER NATURE

© 2021 Springer Nature Switzerland AG. Part of [Springer Nature](https://www.springer.com).